drugset / Trial / NCT00491387

Sympathetic Nervous System Modulation in Hypertension

NCT00491387

Phase 4 Terminated 24 enrolled University of Cincinnati
NaSingle-groupOpen-labelTreatment

Summary

This is a study of patients with high blood pressure who are already treated with an angiotensin converting enzyme inhibitor or receptor blocker and have achieved good or fair blood pressure control. The hypothesis is that addition of the beta-adrenergic receptor blocker, sustained-release metoprolol, will provide additional blockade of the sympathetic nervous system, thereby further improving left ventricular filling and blood pressure control.

Timeline

Start
2007-08
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Metoprolol Other / unclassified 12.5 mg Oral
Subject Metoprolol Other / unclassified 200 mg Oral

Indications